Considerations in the Management of Parkinsonism
Neurol 28:5, Fahn,S.,et al, 1978
Serotonin Syndrome
BMJ 348:g1626, Buckley, N.A.,et al, 2014
Long-Term Effectivenss of Dopamine Agonists and Monoamine Oxidase B Inhibitors Compared with Levodopa as Initial Treatment for Parkinsons Disease (PD MED): A Large, Open-Label, Pragmatic Randomised Trial
Lancet 383: Doi: 10.1016/S0140-6736, PD MED Collaborative Group, 2014
Disorders of the Nervous System Caused by Drugs, Toxins, and Chemical Agents, Monoamine Oxidase Inhibitors
Adams & Victors Principles of Neurology Chp 43, pg 1210, Ropper, A.H.,et al, 2014
Treatment Options in the Modern Management of Parkinson Disease
Arch Neurol 64:1083-1088, Schapira,A.H.V., 2007
The Serotonin Syndrome
NEMJ 352:1112-20, Boyer, E.W. & Shannon, M., 2005
A Controlled Trial of Selegiline, Alpha-Tocopherol, or Both as Treatment for Alzheimer's Disease
NEJM 336:1216-1222, 12451997., Sano,M.,et al, 1997
Pergolide and Selegiline for Parkinson's Disease
The Medical Letter, 31:81-841989., , 1989
Neurotoxicity of Commonly Used Antineoplastic Agents
NEJM 291:75, 1271974., Weiss,H.,et al, 1974
Drug Therapy of Parkinsonism
NEJM 287:20, Yahr,M.,et al, 1972
Neuropsychopharmcology & the Affective Disorders
NEJM 281:197, 1969 (three parts) ., Schildkraut,J.J., 1969